GroundRules
Tex. Government Code § 549.0105: REQUIRED DISCLOSURES IN NEGOTIATIONS FOR SUPPLEMENTAL REBATES.
Where this section sits in the code
- GOVERNMENT CODE
- TITLE 4. EXECUTIVE BRANCH
- SUBTITLE I. HEALTH AND HUMAN SERVICES
- CHAPTER 549. PROVISION OF DRUGS AND DRUG INFORMATION
- SUBCHAPTER C. SUPPLEMENTAL REBATES OR PROGRAM BENEFITS FOR PRESCRIPTION DRUGS
Before or during supplemental rebate agreement negotiations for a prescription drug being considered for the preferred drug list, the commission shall disclose to pharmaceutical manufacturers any clinical edits or clinical protocols that may be imposed on drugs within a particular drug category that are placed on the preferred drug list during the contract period. Clinical edits may not be imposed for a preferred drug during the contract period unless the disclosure is made.
Added by Acts 2023, 88th Leg., R.S., Ch. 769 (H.B. 4611), Sec. 1.01, eff. April 1, 2025.
Collected 2026-08-27T01:47:16Z. Source file · JSON